Hyaluronan and Syndecan‐1: Linking Glycocalyx Degradation to Development and Progression of Heart Failure With Preserved Ejection Fraction
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.044788 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Estela Rocha-Oliveira und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Physiology, Faculty of Medicine of the University of Porto Cardiovascular R&D Center (UnIC@RISE) Porto Portugal. Hauptthemen laut MEDLINE: Hyaluronic Acid, Syndecan-1, Glycocalyx, Heart Failure. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Heart failure with preserved ejection fraction (HFpEF) is characterized by chronic low‐grade inflammation, which influences endothelial function, affecting glycocalyx integrity, barrier permeability, and cell adhesion. The role of endothelial glycocalyx shedding in the onset and progression of HFpEF remains poorly understood. Our aim was to investigate the association of glycocalyx degradation biomarkers, hyaluronan and syndecan‐1, with patient characteristics and clinical outcomes in HFpEF and at population level.
Methods
Circulating hyaluronan and syndecan‐1 concentrations were assessed in a population‐based cohort (STANISLAS [Suivi Temporaire Annuel Non‐Invasif de la Santé des Lorrains Assurés Sociaux], n=959) and a cohort with HFpEF (NETDiamond [New Targets in Diastolic Heart Failure: From Comorbidities to Personalized Medicine], n=86).
Results
Hyaluronan levels increased with age in both the population cohort and the cohort with HFpEF. Higher hyaluronan concentrations were associated in adjusted analyses with features of adverse cardiac remodeling (higher left atrial volume index and left ventricular mass index) in both cohorts and with higher peak early mitral inflow velocity/peak early diastolic mitral annular velocity in the cohort with HFpEF. Syndecan‐1 was negatively associated with left ventricular mass index in the population cohort but not in the cohort with HFpEF where a positive association with features of adverse cardiac remodeling was found. In HFpEF, higher concentrations of both hyaluronan and syndecan‐1 were significantly associated with increased rates of cardiovascular events.
Conclusions
Hyaluronan increases with age and is consistently associated with adverse cardiac remodeling across the spectrum of cardiovascular risk. In HFpEF, a manifestation of advanced cardiovascular disease, both hyaluronan and syndecan‐1 associate with a higher risk of events. These findings suggest that glycocalyx degradation markers provide clinically relevant information across different stages of disease. Whether such markers may serve as therapeutic targets should be further explored.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery and Physiology, Faculty of Medicine of the University of Porto Cardiovascular R&D Center (UnIC@RISE) Porto Portugal.
- Université de Lorraine, INSERM, DCAC Nancy France.
- CHRU Nancy, IHU Infiny Vandoeuvre-les-Nancy France.
- Service d'Anesthésie-Réanimation et Médecine Péri-Opératoire CHRU Nancy-Hôpitaux de Brabois 54500 Vandœuvre-Lès-Nancy France.
- Centre d'Investigation Clinique-Plurithématique (CIC-P) 14-33, CHRU Nancy, INSERM Université de Lorraine Nancy France.
- Cardiovascular and Renal Clinical Trialists Network (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN) Nancy France.
ORCID-Profile: Estela Rocha-Oliveira, Jeremy Lagrange, Guillaume Baudry, Nathalie Mercier, Luca Monzo, Céline Leroy, Zohra Lamiral, Adelino F Leite-Moreira, Faiez Zannad, Joao Pedro Ferreira, Nicolas Girerd
Zitieren
APA
Rocha-Oliveira, E., Lagrange, J., Jahangiri, M., Guerci, P., Baudry, G., Mercier, N., Monzo, L., Leroy, C., Lamiral, Z., Leite-Moreira, A. F., Zannad, F., Ferreira, J. P., Vasques-Nóvoa, F., & Girerd, N. (2026). Hyaluronan and Syndecan‐1: Linking Glycocalyx Degradation to Development and Progression of Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.044788
Vancouver
Rocha-Oliveira E, Lagrange J, Jahangiri M, Guerci P, Baudry G, Mercier N, et al. Hyaluronan and Syndecan‐1: Linking Glycocalyx Degradation to Development and Progression of Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.044788
BibTeX
@article{RochaOliveira2026,
author = {Rocha-Oliveira, Estela and Lagrange, Jeremy and Jahangiri, Mohammad and Guerci, Philippe and Baudry, Guillaume and Mercier, Nathalie and Monzo, Luca and Leroy, Céline and Lamiral, Zohra and Leite-Moreira, Adelino F and Zannad, Faiez and Ferreira, Joao Pedro and Vasques-Nóvoa, Francisco and Girerd, Nicolas},
title = {Hyaluronan and Syndecan‐1: Linking Glycocalyx Degradation to Development and Progression of Heart Failure With Preserved Ejection Fraction},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.044788}
}
EUVIMED